The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
In the central nervous system (CNS), insulin‐like growth factor 1 (IGF‐1) regulates myelination by oligodendrocyte (ODC) precursor cells and shows anti‐apoptotic properties in neuronal cells in different in vitro and in vivo systems. Previous work also suggests that IGF‐1 protects ODCs from cell death and enhances remyelination in models of toxin‐induced and autoimmune demyelination. However, since...
There is an urgent need for therapies that target the multicellular pathology of central nervous system (CNS) disease. Modified, nonanticoagulant heparins mimic the heparan sulfate glycan family and are known regulators of multiple cellular processes. In vitro studies have demonstrated that low sulfated modified heparin mimetics (LS‐mHeps) drive repair after CNS demyelination. Herein, we test LS‐mHep7...
Remyelination failure is considered a major obstacle in treating chronic‐progressive multiple sclerosis (MS). Studies have shown blockage in the differentiation of resident oligodendrocyte progenitor cells (OPC) into myelin‐forming cells, suggesting that pushing OPC into a differentiation program might be sufficient to overcome remyelination failure. Others stressed the need for a permissive environment...